Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teplizumab in Recent Onset Type 1 Diabetes
NCT00378508Phase 2Completed
- Sponsor
- Yale University
- Start
- Sep 2006
- Primary completion
- Aug 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Teplizumab with Placebo (2 arms). Primary endpoint: C-peptide Area Under the Curve Response to a Mixed Meal Tolerance Test at 12 months. Started Sep 2006; status: completed.
02
Drugs
teplizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00378508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00378508.